Inflammatory Bowel Disease: Crossroads of Microbes, Epithelium and Immune Systems
- Epithelial cell and molecular biology, including apoptosis, necrosis and cell survival
- The role of bacterial milieu and mucosal bacteria in the IBD and of prebiotic and probiotic therapy
- The progress towards the identification of susceptibility genes and phenotype-determining genes
- The pharmacogenetics of IBD
- Mucosal immunology and therapeutic strategies stemming therefrom
Progress toward identifying inflammatory bowel disease susceptibility genes (Rioux).
Phenotype-determining genes in inflammatory bowel disease (Ahmad).
Pharmacogenetics of inflammatory bowel disease (Kelleher et al).
Bacterial milieu and mucosal bacteria in ulcerative colitis (Macfarlane et al).
Defensins and mucosal protection (Mahid and Cunliffe).
Intestinal mycoplasma in Crohn's Disease (Roediger).
Kong Probiotics, prebiotics and antibiotics in inflammatory bowel disease (Cummings and Choon).
The eipthelium in inflammatory bowel disease: potential role of endocytosis of junctional proteins in barrier disruption (Ivanov et al).
Apoptosis or necrosis - colonic epithelial cell survival (Gibson).
Genetic aspects of intestinal permeability in inflammatory bowel disease (Takeuchi et al).
Animal models of intestinal inflammation: clues to the pathogenesis of inflammatory bowel disease (Powrie and Uhlig).
Homing of intestinal immune cells (Uhlig et al).
Anti-TNF therapy in Crohn's Disease (Ghosh).
Index of contributors.